In the present study, we analyzed the function of a novel mutation (c.1628T4G, p.Leu543Trp) in the solute carrier organic anion transporter (SLCO) 1B1 gene, encoding organic anion transporting polypeptide (OATP) 1B1, which was identified in a patient with pravastatin-induced myopathy. OATP1B1 variants carrying the mutation (OATP1B1*1a þ c.1628T4G or *1b þ c.1628T4G) showed a reduced transporting activity toward typical substrates and pravastatin compared with the activity of the references (OATP1B1*1a or *1b). This was due to reduction in V max values of the variants, not due to change in their K m values. OATP1B1*1b þ c.1628T4G was normally expressed on the plasma membrane of HEK293 cells at the same level as that of OATP1B1*1b. Taken together, our results suggest that the mutation c.1628T4G (p.Leu543Trp) reduced the function of OATP1B1 probably due to decrease in turnover rate of one OATP1B1 molecule rather than impairment of protein sorting to the plasma membrane.
Introduction
Organic anion transporting polypeptide (OATP) 1B1 (gene symbol SLCO1B1, also known as OATP2, 1 LST- 1 2 ) is a member of the membrane solute carrier family and is specifically expressed in hepatocytes at the basolateral side.
3 OATP1B1 can uptake structurally diverse drugs, such as 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), 1 SN-38 4 and rifampicin, 5 from circulation in a sodium-independent manner. With its high level of expression in the liver and its substrate polyspecificity, OATP1B1 is one of the major determinants of pharmacokinetics of various drugs. Therefore, impaired function of OATP1B1 caused by genetic polymorphisms would greatly affect plasma concentrations of substrate drugs, which may result in decrease in efficacy of the drugs or in increase in the risk of development of adverse effects. For example, it has been reported that carriers of the single nucleotide polymorphism (SNP), c.521T4C (p.Val174Ala), OATP1B1*5 or *15, show increased plasma concentrations of pravastatin, 6 -8 repaglinide 9 and simvastatin. 10 Severe toxicity after irinotecanbased chemotherapy for lung cancer has also been reported in a patient with a homozygote for the SLCO1B1*15 allele, which carries the SNP c.521T4C (p.Val174Ala).
The SLCO1B1 gene possesses many SNPs and mutations. Although not all, some of them have been demonstrated to significantly affect the function of OATP1B1. The SNP c.521T4C (p.Val174Ala), located within the fourth transmembrane domain, has been shown to impair membrane localization of OATP1B1 in cultured cells, causing remarkable loss of the function of the transporter. 12, 13 This is in agreement with in vivo findings described above. The SNP c.578T4G (p.Leu193Arg) and the SNP c.1058T4C (p.Ile353Thr) are also located within the fourth and seventh transmembrane domains, respectively, and have been reported to reduce the expression level of OATP1B1 protein in the plasma membrane without significant effects on total protein expression level in a cell-based system. 13, 14 Another SNP located in the second transmembrane domain, c.217T4C (p.Phe73Leu), has been reported to reduce the level of total protein expression. Collectively, the SNPs located in the transmembrane domain likely result in reduction in the level of transport activity either due to impairment of membrane sorting or due to impairment of expression of OATP1B1.
We recently reported that there was a novel nonsynonymous mutation in the SLCO1B1 gene (c.1628T4G, ss107796321). 15 However, in vivo and in vitro functions of the mutation have remained unknown. The mutation seems to be rare because it was not found in any of the 50 DNA samples from healthy Japanese volunteers, 15 and it has been reported that the mutation was not found in the 285 DNA samples from Caucasian. 16 Nevertheless, the function of the mutation should be clarified because the mutation was found in a patient with pravastatin-induced myopathy who did not possess any mutations that have been reported to decrease the function of OATP1B1. The mutation generates an amino-acid substitution, p.Leu543Trp, that is located within the 10th transmembrane domain. Considering the reports mentioned above, it is likely that the mutation c.1628T4G (p.Leu543Trp) reduces the transport activity of OATP1B1 protein.
In the present study, we characterized the mutation c.1628T4G (p.Leu543Trp) in OATP1B1 by using transient and stable expression systems. Our results showed that the mutation resulted in decrease in the transport activity in both systems. The results also indicated that the decrease in the activity of OATP1B1 was not due to impairment of protein sorting to the plasma membrane and that the mechanism of c.1628T4G causing reduction in the function of OATP1B1 is distinct from the mechanisms of the other SNPs located in the transmembrane domain of OATP1B1.
Results
Effect of c.1628T4G (p.Leu543Trp) on the uptake activity of OATP1B1 toward typical substrates To determine the effect of c.1628T4G (p.Leu543Trp) on the function of OATP1B1, we examined the uptake activities of OATP1B1 toward estradiol-17b glucuronide (E 2 17bG) and estrone-3-sulfate (E 1 3S) in human embryonic kidney (HEK) 293 cells transiently expressing OATP1B1 allelic variants, OATP1B1*1a, *1b, *1a þ c.1628T4G and *1b þ c.1628T4G (Figure 1a) . All of the variants showed significant transport activity in the two substrates compared with the activity of mock-transfected cells. When E 2 17bG was used, the levels of transport activity of OATP1-B1*1a þ c.1628T4G and *1b þ c.1628T4G were 55% (Po0.005) and 49% (Po0.005) of those of OATP1B1*1a and *1b, respectively. Although the differences were not statistically significant, the levels of E 1 3S transport activity of OATP1B1*1a þ c.1628T4G and *1b þ c.1628T4G were smaller than those of OATP1B1*1a and *1b (81 and 70%, respectively). No significant difference between the activities of OATP1B1*1a and *1b or between the activities of OATP1B1*1a þ c.1628T4G and *1b þ c.1628T4G was observed in all cases. The results of reverse transcriptasepolymerase chain reaction (RT-PCR) and quantitative realtime PCR showed that there was no significant difference in the levels of mRNA expression of the OATP1B1 variants in this assay system (Figure 1b) .
Effect of c.1628T4G (p.Leu543Trp) on the uptake activity of OATP1B1 toward pravastatin Given the results showing that c.1628T4G (p.Leu543Trp) affected the function of OATP1B1, we also examined pravastatin transport activity of OATP1B1 carrying c.1628T4G (Figure 2 ). The levels of pravastatin transport activity of OATP1B1*1a þ c.1628T4G and *1b þ c.1628T4G were 52% (Po0.05) and 42% (Po0.01) of those of OATP1-B1*1a and *1b, respectively. No significant difference between the activities of OATP1B1*1a and *1b or between the activities of OATP1B1*1a þ c.1628T4G and *1b þ c.1628T4G was observed.
Determination of kinetic parameters of pravastatin transport
To determine the effect of c.1628T4G (p.Leu543Trp) on kinetic parameters of pravastatin transport of OATP1B1, we analyzed the concentration dependence of pravastatin transport in HEK293 cells transiently expressing OATP1B1 variants ( Figure 3) . The concentration to reach halfmaximum uptake rate (K m ) values of pravastatin transport were not significantly different among the OATP1B1 variants, whereas the maximum uptake rate (V max ) values of OATP1B1*1a þ c.1628T4G and *1b þ c.1628T4G were 41 and 60% less than those of OATP1B1*1a and *1b, respectively. The kinetic parameters determined are summarized in Table 1 .
Examination of membrane sorting of OATP1B1*1b and *1b þ c.1628T4G and their fusion proteins in HEK293 cells To examine whether reduction of the function of OATP1B1 is due to impairment of membrane sorting of the protein, we performed immunocytochemical analysis. We used OATP1B1*1b as a reference type because c.1628T4G (p.Leu543Trp) was originally detected on the SLCO1B1*1b allele. OATP1B1*1b transiently expressed in HEK293 cells was detected on the plasma membrane and, accordingly, OATP1B1*1b þ c.1628T4G in HEK293 cells was also detected on the plasma membrane (Figure 4a ). No expression of OATP1B1 was detected in the mock-transfected cells. In addition, we examined localization of fusion proteins of OATP1B1 variants with green fluorescence protein (GFP) (Figure 4b ). Green fluorescence was detected on the plasma membrane in both cells expressing OATP1B1*1b-GFP and *1b þ c.1628T4G-GFP, whereas fluorescence was detected throughout the cells in mock-transfected cells. 
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T Furihata et al OATP1B1*1b þ c.1628T4G was slightly larger than that of OATP1B1*1b ( Figure 5a ). HEK293 cells stably expressing OATP1B1 variants showed a higher level of activity than that of cells transfected with a mock plasmid (Po0.005), and this activity was completely inhibited by the presence of bromosulfophthalein (BSP, 10 mM) ( Figure 5b ). When kinetic parameters of E 2 17bG for OATP1B1*1b or *1b þ c.1628T4G were determined, K m values were 8.3±4.0 and 7.8±2.2 mM and V max values were 102.7 ± 24.9 and 64.0 ± 8.8 pmol min À1 per mg protein, respectively (data not shown). These results were similar to the results obtained from the transient expression system.
Western blotting was performed using the cells ( Figure 6 ). The levels of OATP1B1 protein expression in total membrane fractions were similar for cells expressing OATP1B1*1b and *1b þ c.1628T4G, and no apparent expression was observed in mock-transfected cells. Similar amounts of protein loaded were confirmed by the level of band intensity of Na þ /K þ ATPase. When the levels of expression of OATP1B1 variants in cell membrane proteins were compared, there was no distinguishable difference. Again, no apparent expression of OATP1B1 was observed in mocktransfected cells, and similar amounts of protein loaded were confirmed by the level of band intensity of Na þ /K þ ATPase. Calnexin, an endoplasmic reticulum membrane protein, was detected in the total membrane proteins but not in the cell-surface proteins, confirming no contamination of intracellular membrane proteins in the cell-surface proteins.
Discussion
The results of the present study using a transient expression system showed that the activity levels of OATP1-B1*1a þ c.1628T4G and *1b þ c.1628T4G were significantly lower than those of OATP1B1*1a and *1b, respectively, for not only E 2 17bG, but also for an exogenous substrate, pravastatin. In addition, the results of kinetic analysis showed that the V max values of OATP1-B1*1a þ c.1628T4G and *1b þ c.1628T4G for pravastatin uptake were decreased by 41 and 60%, respectively, whereas K m values were not different among the OATP1B1 variants studied. These findings suggest that the mutation Effect of a mutation (c.1628T4G) on the function of OATP1B1
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or decrease in the turnover rate of one OATP1B1 molecule. Therefore, we further examined the mechanism for reduction of V max . The results of fluorescent microscopic analyses and cell-surface biotinylation analysis showed that OATP1B1*1b þ c.1628T4G was normally expressed and localized on the plasma membrane in HEK293 cells. These findings suggest that the decrease in maximum velocity for the transporting activity of OATP1B1 was not derived from reduction in the level of functional OATP1B1 protein expression on the plasma membrane. It has been reported that amino-acid substitutions within the transmembrane domain, the SNP c.217T4C (p.Phe73-Leu), the SNP c.521T4C (p.Val174Ala), the SNP c.578T4G (p.Leu193Arg) and the SNP c.1058T4C (p.Ile353Thr), all cause loss of function of OATP1B1 due to decrease in the expression level of OATP1B1 protein. [12] [13] [14] For example, the variant OATP1B1 þ c.217T4C showed a decrease in total level of protein expression, whereas OATP1B1 þ c.521T4C, þ c.578T4G and þ c.1058T4C exhibited decreased amounts of expression on the plasma membrane with no significant change in total expression level when compared with that of the reference type. On the other hand, the mutant gene examined in the present study showed intact expression and membrane localization, although the position of the substituted amino acid is within the transmembrane domain. The findings indicate that the function of c.1628T4G (p.Leu543Trp) is quite different from that of other SNPs located in the transmembrane domain. The exact reason for this difference is unclear, but the difference may be due to both the position and manner of the mutation. The leucine at position '543' is not highly conserved among mammalian OATP1 family members, whereas the amino acids at positions '73', '174', '193' and '353' are highly conserved. 17 Thus, the amino acid at position '543' seems promiscuous. In addition, the tryptophan at this position could be permissible to build the transmembrane domain because it is as hydrophobic as the leucine. This hydrophobically similar alternation at a less conserved position could explain why OATP1B1*1b þ c.1628T4G was normally expressed and localized to the plasma membrane in HEK293 cells without apparent abnormality.
Nevertheless, c.1628T4G (p.Leu543Trp) affected the transport ability of OATP1B1, which is the first example showing that the mutation in the transmembrane domain of OATP1B1 causes reduction of transport ability without affecting substrate affinity. This finding indicates that the leucine at this position is important in substrate transport. The functions of the leucine in substrate transport were further characterized by the results showing that the effect of c.1628T4G (p.Leu543Trp) was substrate dependent because the decrease in level of transport activity was not significant in E 1 3S. Tirona et al. 13 reported that the effect of the SNP c.1964A4G (p.Asp655Gly) was more significant on E 1 3S transport than on E 2 17bG transport. Michalski et al. 14 reported that the SNP c.463C4A (p.Pro155Thr) caused complete loss of transport activity of OATP1B1 toward choryltaurine but not toward BSP. Taken together with facts that 655Asp was in the C-terminal cytoplasmic tail, 155Pro was in the second extracellular loop and 543Leu was in the 10th transmembrane domain, the findings suggest that each SNP has a distinct effect on substrate transport depending on its position. Because the function of the 10th transmembrane in substrate transport has not been clarified, the function of 543Leu in substrate transport is currently unknown. However, considering that c.1628T4G (p.Leu543Trp) did not affect substrate affinity and that the tryptophan possesses a more bulky side chain than does the leucine, it is speculated that the mutation changes the structure of the pore through which substrates are passed, resulting in physical disturbance of the movement of substrates. It has been shown that there are two distinct components for E 1 3S transport 18, 19 and that gemfibrozil inhibits only the high-affinity low-capacity component. 18 Therefore, it is possible that the change in pore structure caused by the mutation affected only the high-affinity lowcapacity component of E 1 3S transport. Although we do not precisely know how c.1628T4G (p.Leu543Trp) worked in the present experiments, our results provide important information for understanding the regions of OATP1B1 responsible for substrate transport, which have remained elusive.
Coupled with the fact that c.1628T4G (p.Leu543Trp) was originally identified in a patient with pravastatin-induced myopathy, the function of c.1628T4G (p.Leu543Trp) to reduce the level of pravastatin transport activity of OATP1B1 is reminiscent of reports that carriers of SLCO1B1*5 or *15, the haplotype carrying SNP c.521T4C (p.Val174Ala), showed aberrant pravastatin pharmacokinetics. Mwinyi et al. 8 reported that the area under the concentration curve (0-6 h) in SLCO1B1*1a/*5 carriers (n ¼ 10) was 1.4-fold larger than that in SLCO1B1*1a/*1a carriers (n ¼ 10). Nishizato et al. 6 reported that nonrenal clearances of pravastatin in SLCO1B1*1b/*15 carriers (n ¼ 9) and in SLCO1B1*15/*15 carriers (n ¼ 1) were 55 and 13%, respectively, of that in SLCO1B1*1b/*1b carriers (n ¼ 4). Therefore, although the Cell-surface biotinylation analysis was performed and OATP1B1 variants were detected by western blotting. Total membrane proteins were prepared just before collection of cell-surface proteins, and the biotinylated proteins were collected to be used as cellsurface proteins, using streptoavidin. Na þ /K þ ATPase was used for the plasma membrane marker, and calnexin was used for the marker of intracellular membrane protein.
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In conclusion, our results show that the mutation c.1628T4G (p.Leu543Trp) in the SLCO1B1 gene causes reduction of the level of transport activity of OATP1B1 toward pravastatin and typical substrates. The results indicate that the mechanism causing this reduction is not impairment of plasma membrane localization but rather reduction of turnover rate of one OATP1B1 molecule. Although it currently remains unclear how c.1628T4G (p.Leu543Trp) in OATP1B1 affects substrate transport, this is the first example showing that the mutation in the transmembrane domain of OATP1B1 reduces the level of substrate transport with lack of effects on substrate affinity. Therefore, the mutation c.1628T4G (p.Leu543Trp) has some important implications in the mechanisms by which OATP1B1 transports its substrate.
Materials and methods
cDNA cloning and construction of OATP1B1 expression plasmid carrying c.1628T4G
The procedures for cDNA cloning of OATP1B1*1a and *1b were described in the previous report.
12 Site-directed mutagenesis by PCR was performed to generate the variants, OATP1B1*1a þ c.1628T4G and *1b þ c.1628T4G. The primers, sense 5 0 -GCAATACAAGTCTGGAATTTATTTTTC-3 0 and antisense 5 0 -GAAAAATAAATTCCAGACTTGTATTGC-3 0 , and KOD-Plus (Toyobo, Osaka, Japan) were used for the mutagenesis. The DNA sequence was determined using a Dye Terminator Cycle Sequencing-Quick Start Kit (Beckman Coulter, Fullerton, CA, USA) and a CEQ 2000 DNA Analysis System (Beckman Coulter). The results were confirmed by sequencing at least twice in each direction. The plasmids constructed were referred to as OATP1B1*1a þ c.1628T4G and *1b þ c.1628T4G.
pAcGFP-C1 plasmid was purchased from Clontech Laboratories (Palo Alto, CA, USA). OATP1B1*1b or *1b þ c.1628T4G cDNA was inserted into the pAcGFP-C1 plasmid downstream of the GFP coding region by using an In-Fusion Dry-Down PCR Cloning kit (Clontech). The coding region of OATP1B1*1b or *1b þ c.1628T4G cDNA was amplified by nested-PCR and the PCR products were purified. The PCR products (80 mg) was mixed with pAcGFP-C1 plasmid (90 mg) that had been linearized by KpnI digestion, and the mixture was incubated with the reaction beads for 15 min at 37 1C, followed by incubation for 15 min at 50 1C. The reaction mixture was used for transformation. The plasmids obtained were referred to as OATP1B1*1b-GFP and *1b þ c.1628T4G-GFP.
Cell culture and transfection HEK293 cells were obtained from Human Health Science Research Bank (Osaka), and they were cultured in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) inactivated fetal bovine serum, 50 U per ml penicillin and 50 mg ml À1 streptomycin at 37 1C with 5% CO 2 . The procedure for transient transfection was described previously. 12 Briefly, HEK293 cells seeded in a poly-D-lysinecoated 12-well plate (Becton Dickinson, Franklin Lakes, NJ, USA) at 4 Â 10 5 cells per ml were transiently transfected with 3 mg of the OATP1B1 expression plasmids using Lipofectamine2000 (Invitrogen) according to manufacturer's protocol. Sodium butyrate (Sigma-Aldrich, St Louis, MO, USA) was added to the medium at 5 mM final concentration. After 24 h of incubation, cells were used for transport assays or harvested for RT-PCR and real-time PCR.
For establishment of cells stably expressing OATP1B1 allelic variants, HEK293 cells were seeded in a 60-mm dish. They were transfected with 10 mg of the OATP1B1 expression plasmids, which had been linearized by ScaI treatment, by using Lipofectamine LTX (Invitrogen) according to manufacturer's protocol. After 1 day of culture, the cells were exposed to Zeocin (Invitrogen) at 200 mg ml À1 for 3 weeks. When the selection was completed, the cells were individualized and expression of OATP1B1 allelic variant was analyzed by determining uptake activity of E 2 17bG according to the methods described below. Expression of OATP1B1 allelic variant was also confirmed by RT-PCR and real-time PCR.
Total RNA extraction, cDNA synthesis, RT-PCR and quantitative real-time PCR Total RNAs were extracted from the cells by using a FastPure RNA kit (Takara, Shiga, Japan) according to the manufacturer's protocol. No genomic DNA contamination was confirmed by performing PCR as described previously. 20 The method of cDNA synthesis was also described previously. 20 PCR was performed with the primers 5 0 -TGTCA TTGTCCTTTTACCTATTAT-3 0 (sense) and 5 0 -TGTAAGTTATT CCATTGTTTCCAC-3 0 (antisense) for detection of OATP1B1 allelic variant and with the primers 5 0 -TGCACCACCAAC TGCTTA-3 0 (sense) and 5 0 -GGATGCAGGGATGATGTTC-3 0 (antisense) for detection of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Nucleotide sequences of PCR products were analyzed as described above. The expression levels of OATP1B1 mRNA were also quantitatively analyzed by using TaqMan Gene Expression Assays with an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) as described previously. 20 The expression level of GAPDH was used as an internal standard and was used for normalization of the expression level of the objective gene. ) were purchased from PerkinElmer Life Sciences (Boston, MA, USA). Pravastatin was kindly provided by Sankyo Co. Ltd (Tokyo, Japan). Determination of transporting activity of E 2 17bG (0.5 mM), E 1 3S (0.05 mM) or pravastatin (20 mM) in the cells transiently expressing OATP1B1 allelic variants was performed as described Effect of a mutation (c.1628T4G) on the function of OATP1B1 T Furihata et al previously. 12 The methods for the cells stably expressing OATP1B1 allelic variants were essentially the same as those described above, but exceptions were that sodium butyrate (10 mM) was added to the medium 1 day before transport assay and that transport assay of E 2 17bG (0.1 mM) was performed in the presence or absence of BSP (10 mM). Protein determination was performed by using a DC Protein Assay Kit II (Bio-Rad Laboratories, Hercules, CA, USA).
Determination of transporting activity
For kinetics analysis, pravastatin transporting activities were determined with the concentrations of 5, 10, 20, 50 and 100 mM and E 2 17bG transporting activities were determined with the concentrations of 0.5, 1, 5, 10, 20 and 50 mM. The OATP1B1-mediated uptake was calculated after subtracting the uptake by the mock cells from the uptake by OATP1B1-expressing cells at each concentration. MichaelisMenten-type nonlinear curve fitting was carried out to obtain kinetic parameters (Delta Graph 4.5; RockWare Inc., Golden, CO, USA).
Preparation of total membrane proteins and cell-surface membrane proteins Cell-surface biotinylation was performed by using a Pinpoint Cell Surface Protein Isolation kit (Pierce, Rockford, IL, USA) according to the manufacturer's protocol. Briefly, HEK293 cells stably expressing OATP1B1*1b or *1b þ c.1628T4G and the mock-transfected cells were cultured in the medium containing 10 mM sodium butyrate for 1 day. The cells were washed with phosphate-buffered saline (PBS) containing 1 mM Ca 2 þ and 1 mM Mg 2 þ (Mg 2 þ / Ca 2 þ -PBS), and they were treated with EZ-link Sulfo-NHS-SS-Biotin (Pierce) for 30 min at 4 1C. The biotinylation solution was removed and quenching solution in Mg 2 þ / Ca 2 þ -PBS was added to the cells, and the cells were incubated for 5 min. The cells were scraped and centrifuged at 1500 g for 10 min. The pellets were washed with Trisbuffered saline and centrifuged at 1500 g for 10 min. The pellets were resolved and incubated in the lysis buffer for 30 min at 4 1C with frequent sonication and vortexing. The solution was centrifuged at 10 000 g for 2 min at 4 1C, and the supernatant was collected and its protein concentration was determined as described above. This sample was used as total membrane proteins. An equal amount of proteins of each sample was incubated with Immobilized NeutrAvidin Gel (Peirce) in the column for 1 h at room temperature. The column was centrifuged at 1000 g for 1 min and washed six times with the supplied buffer. The column was incubated in the solubilization buffer for western blotting (mixture of equal volumes of SET buffer and buffer containing 66 mM NaCl, 140 mM Tris, 20% glycerol, 0.0027% pyronin Y, 2 mM EDTA, 100 mM dithiothreitol, protease inhibitor cocktail set III (Sigma-Aldrich) and 4% SDS, pH 6.8) with stirring at room temperature. The proteins were eluted by centrifugation.
Western blotting
Western blotting was performed as previously reported 13 with some modifications. Total membrane proteins (30 mg) and cell-surface proteins (30 ml) in the solubilization buffer for western blotting were incubated in a water bath for 10 min at 37 1C. SDS-polyacrylamide gel (SDS-PAGE) electrophoresis was performed with 10% PAGE containing 0.2% deoxycholic acid sodium salt (Sigma-Aldrich). The proteins were transferred to a polyvinylidene difluoride membrane in transblotting buffer (25 mM Tris, 0.2 M glycine, 0.02% SDS in methanol/water ¼ 1:4) for 2 h at 1 mA per 1 cm 2 . The membrane was blocked with 3% bovine serum albumin for 1 h at room temperature. The membrane was incubated with primary antibodies, rabbit anti-human LST-1 IgG (1000-fold dilution; Alpha Diagnostic International, San Antonio, TX, USA), mouse anti-Na þ /K þ ATPase IgG (250-fold dilution; Sigma-Aldrich) or anti-calnexin IgG (5000-fold dilution; Stressgen, Ann Arbor, MI, USA), overnight at 4 1C and then for 1 h at room temperature. Donkey anti-rabbit IgG, horseradish peroxidase-linked whole antibody (GE Healthcare) and goat anti-mouse IgG, peroxidase conjugate (SigmaAldrich) were used as secondary antibodies for anti-human LST-1 rabbit IgG, anti-calnexin IgG and anti-Na þ /K þ ATPase mouse IgG, respectively. Detection of chemiluminescence was performed with an enhanced chemiluminescence western blotting analysis system (GE Healthcare) and LAS-1000 plus (Fujifilm, Tokyo, Japan).
Confocal laser scanning microscopy
Immunofluorescence microscopy was performed by using a FluorView FV-500 (Olympus, Tokyo, Japan) as described previously. 12 The primary antibodies were anti-human LST-1 rabbit IgG (50-fold dilution), and the secondary antibodies were rabbit IgG labeled with Alexa Fluor 488 (60 mg ml À1 ) by an anti-rabbit IgG labeling kit (Invitrogen).
For the examination of localization of the fusion proteins, OATP1B1*1b-GFP, *1b þ c.1628T4G-GFP or empty pAcGFP-1-C1 was transiently transfected to HEK293 cells as described above. After 24 h, the cells were washed with PBS and the cellular proteins were fixed with 4% formaldehyde for 30 min at room temperature. The green fluorescence was analyzed by using FluorView FV-500.
Statistical analysis
Statistical analysis was performed by Student's t-test or oneway analysis of variance (ANOVA) (Statcel software; OMS Publishing Inc., Tokyo, Japan). 
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